Mantle Cell Lymphoma

Michael Wang, MD, discusses the real-world efficacy of brexucabtagene autoleucel, the first chimeric antigen receptor T-cell therapy for the treatment of mantle cell lymphoma.

A study at MD Anderson Cancer Center aims to evaluate ixazomib and rituximab in patients with relapsed or refractory mantle cell lymphoma.

Luhua Wang, MD, discussed the impact that the approval of the CAR T-cell therapy brexucabtagene autoleucel has had on mantle cell lymphoma.

According to Tycel Jovelle Phillips, MD, the study of venetoclax in combination with the R2 regimen will be expanded to include 50 patients with mantle cell lymphoma without a TP53 mutation.

Results from a mantle cell lymphoma study provide critical real-world evidence for improved outcomes with evolving patterns of care in patients with mantle cell lymphoma, according to the study authors.

In an interview with Targeted Oncology, Michael Wang, MD, discussed the evolution of treatment in the MCL space specifically with the emergence of chimeric antigen receptor T cells.

Outcomes for patients with mantle cell lymphoma are poor after ibrutinib fails, pointing to a need for the development of safe and effective targeted therapies.

Tycel Jovelle Phillips, MD, discusses the design of a phase 1 study looking at venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma.

The long-term efficacy of autologous hematopoietic stem cell transplantation in mantle cell lymphoma has been evaluated and confirmed 15 years later.

Peter Riedell, MD, an assistant professor of medicine at University of Chicago Medicine, discusses outcomes for mantle cell lymphoma patients and the impact of the timing of relapse on overall survival after autologous stem cell transplantation.

Inhibition of the Bruton’s tyrosine kinase (BTK) has shown potency in B-cell malignancies, leading to the exploration of treatment with the BTK inhibitor LOXO-305 in patients with mantle cell lymphoma (MCL) in the phase 3 BRUIN clinical trial.

Peter Martin, MD, explains the importance of reviewing real-world databases and the results of a real-world study of treatment patterns and outcomes of patients with mantle cell lymphoma.

Peter A. Riedell, MD, discusses the clinical implication of using frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation in patients with mantle cell lymphoma in an analysis of time to relapse.

In an interview with Targeted Oncology, Peter Martin, MD, discussed the real-world findings and how future agents should be developed to ensure optimal benefit for all patients with mantle cell lymphoma.

Peter Martin, MD, provides his expert opinion on how to close the gap between recommended treatment pattens for mantle cell lymphoma and patterns observed in the real-world setting.

The FDA has granted breakthrough therapy designation to orelabrutinib, a Bruton’s tyrosine kinase inhibitor, for the treatment of relapsed or refractory mantle cell lymphoma.

In an interview with Targeted Oncology, Peter Riedell, MD, discussed an analysis of how time to relapse impacts survival. He also explained what the study findings mean for clinical practice.

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials, according to a poster presented at the European Hematology Association 2021 Virtual Congress.

Peter Riedell, MD, discusses the effect of time to relapse in patients with mantle cell lymphoma after frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation.

Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma, according to a retrospective analysis presented at the European Hematology Association 2021 Virtual conference.

The combination of cirmtuzumab and ibrutinib achieved high overall response rates in patients with mantle cell lymphoma or chronic lymphocytic leukemia who were treated in a phase 1/2 study.

Mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors displayed anti-tumor activity on treatment with tazemetostat as monotherapy or in combination with zanubrutinib, according to data from a preclinical analysis.

Patients with mantle cell lymphoma treated with second-line ibrutinib or the R-BAC regimen experienced improvement in progression-free survival 2 compared with treatment on rituximab and bendamustine and other regimens, according to findings from the international, retrospective MANTLE-FIRST study.

According to a new study, marital status and education level may impact treatment and overall outcomes for patients with mantle cell lymphoma.

A new report on ibrutinib-resistant mantle cell lymphoma patient-derived xenograft mouse models shows the potential benefit of the EZH1/2 inhibitor OR-S1, as other similar inhibitors have shown benefit in patients with hematologic cancers.

Pirtobrutinib showed promising efficacy and safety as treatment of patients with mantle cell lymphoma, demonstrating the potential to serve an unmet medical need.

In an interview with Targeted Oncology, Hun Ju Lee, MD, summarized the findings and future steps for the study of cirmtuzumab in patients with mantle cell lymphoma.

In relapsed and untreated patients with mantle cell lymphoma, the combination of obinutuzumab, ibrutinib, and venetoclax achieved molecular response rates and was found to be well tolerated, results from the phase 1/2 OAsIs trial demonstrate.

In an interview with Targeted Oncology, Maria Lia Palomba, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center, discussed the efficacy and safety of liso-cel in patients with R/R MCL as observed in the phase 1 TRANSCEND NHL 001 study.

Andre Goy, MD, MS, discusses the results of the ZUMA-2 study of the chimeric antigen receptor T-cell therapy